Abstract
A range of ligands displayed agonism at the long isoform of the human dopamine D2 receptor, whether using receptor-G protein fusions or membranes of cells in which pertussis toxin-resistant mutants of individual Gαi-family G proteins could be expressed in an inducible fashion. Varying degrees of efficacy were observed for individual ligands as monitored by their capacity to load [35S]GTPγS onto each of Gαi1,Gαi2,Gαi3, and Gαo1. By contrast, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine was a partial agonist when Gαo1 was the target G protein but an antagonist/inverse agonist at Gαi1,Gαi2, and Gαi3. In ligand binding assays, dopamine identified both high- and low-affinity states at each of the dopamine D2 receptor-G protein fusion proteins, and the high-affinity state was eliminated by guanine nucleotide. (S)-(–)-3-(3-Hydroxyphenyl)-N-propylpiperidine bound to an apparent single state of the constructs in which the D2 receptor was fused to Gαi1,Gαi2, or Gαi3. However, it bound to distinct high- and low-affinity states of the D2 receptor-Gαo1 fusion, with the high-affinity state being eliminated by guanine nucleotide. Likewise, although dopamine identified guanine nucleotide-sensitive high-affinity states of the D2 receptor when expression of pertussis toxin-resistant forms of each of Gαi1, Gαi2, Gαi3, and Gαo1 was induced, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine identified a high-affinity site only in the presence of Gαo1. p-Tyramine displayed a protean ligand profile similar to that of (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine but with lower potency. These results demonstrate (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine to be a protean agonist at the D2 receptor and may explain in vivo actions of this ligand.
Footnotes
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.106.032722.
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; 7-OH-DPAT, R-(+)-7-hydroxy-2-dipropylaminotetralin hydrobromide; D2L, long isoform of the human dopamine D2 receptor; [35S]GTPγS, guanosine 5′-O-(3-[35S]thio)triphosphate; NPA, R-(–)-10,11-dihydroxy-N-n-propylnorapomorphine; R-(+)-3-PPP, (R)-(+)-3-(3-hydroxyphenyl)-N-propylpiperidine; S-(–)-3-PPP, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine; PCR, polymerase chain reaction; HEK, human embryonic kidney.
- Received November 15, 2006.
- Accepted February 7, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|